---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-268134"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:35:07.390373+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Whitehawk Therapeutics reports Q3 net loss of $17.7M, cash $162.6M, IND filings on track

## Summary
- Net loss for Q3 2025 was $17.7M vs $12.5M in Q3 2024; no revenue reported.
- Cash, equivalents and short-term investments $162.6M as of Sept 30, 2025, up from $47.2M at Dec 31, 2024; runway into 2028.
- IND submissions for HWK-007 and HWK-016 planned by year-end 2025; HWK-206 by mid-2026.
- PTK7 confirmed as broadly expressed tumor target through analysis presented at AACR-NCI-EORTC.
- Management expects initial clinical data readouts across portfolio from current cash position.

## SEC filing metadata
- accession: 0001193125-25-268134
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312525268134/0001193125-25-268134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312525268134/whwk-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-268134
- JSON: https://secwatch.observer/filing/0001193125-25-268134.json
- Plain text: https://secwatch.observer/filing/0001193125-25-268134.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.